Creating powerful collaborations that deliver impact in cell and gene therapies

Overcoming current challenges to the advancement of the sector

We are committed to identifying solutions to the key challenges affecting cell and gene therapy development, manufacture, and patient delivery. These challenges include:

• Developing new therapeutics

  Delivering a strong pipeline of novel ATMPs that not only demonstrate high clinical efficacy but also extend their impact to a broader range of diseases.

• High cost of goods

  Manufacturing costs for ATMPs remain prohibitively high, limiting accessibility and scalability.

• Ensuring strong supply

  The sector needs a fully robust and scalable manufacturing infrastructure to support the growing and dynamic demands of this rapidly expanding field.

• Achieving broader patient access

  Routinely integrating ATMPs into healthcare systems remains a challenge, with complex reimbursement models and adoption pathways slowing the rate at which these treatments reach patients. 

Creating opportunities across the UK

Our outputs leverage research, transform barriers into industrial advantage and help to attract new investment for our collaborators.

We support people in acquiring new skills, organisations in establishing new capabilities, and policymakers in developing new perspectives.